KCT0002038Recruiting未知
Response-based treatment of high-risk neuroblastoma
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Samsung Medical Center
- Enrollment
- 54
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- o Limit to o Limit (—)
- Sex
- All
Inclusion Criteria
- •1. Patients with newly diagnosed high risk neuroblastoma
- •2. Patients with measurable or evaluable disease
- •3. Patients with informed consent
Exclusion Criteria
- •1. Patients with progressive disease or relapse
- •2. Patients who underwent high dose chemotherapy before
- •3. Patients with organ dysfunction as follows (creatinine elevation > 3 x upper limit of normal, Total bilirubin > 3 x upper limit of normal, aspartate transaminase/alanine transaminase > 5 x upper limit of normal), ejection fraction <40%)
- •4. Pregnant or nursing women
Investigators
Similar Trials
Unknown
Phase 2
Response-based Treatment of High-risk NeuroblastomaNewly Diagnosed High Risk NeuroblastomaNCT02771743Samsung Medical Center54
Completed
Not Applicable
ovel treatment for refractory neuroblastoma by using poliovirus; phase I clinical trialrefractory neuroblastomaJPRN-UMIN000029816Mie University3
Active, not recruiting
Phase 1
Study for the low and intermediate risk NeuroblastomaINTERMEDIATE AND LOW RISK NEUROBLASTOMAMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021396-81-PTInstituto de Investigación Sanitaria La Fe de Valencia520
Completed
Phase 2
Combination Chemotherapy or Observation Following Surgery in Treating Infants With NeuroblastomaNeuroblastomaNCT00002803Children's Hospital Medical Center, Cincinnati44
Active, not recruiting
Phase 1
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01GanglioneuroblastomaNeuroblastomaNCT02311621Seattle Children's Hospital65